Literature DB >> 7529989

Localization of four antigenic sites involved in Venezuelan equine encephalomyelitis virus protection.

E V Agapov1, I A Razumov, I V Frolov, A A Kolykhalov, S V Netesov, V B Loktev.   

Abstract

Stable neutralization and protection escape variants of a virulent strain (Trinidad Donkey) of the VEE virus were selected by monoclonal antibodies (MAbs). Determination of nucleotide sequences of nine variants revealed a clustering of single mutations in four regions of the E1 and E2 glycoproteins. Involvement of amino acid residues 206 (site E1-1), 57 and 59 (site E2-2), 180, 182, 213, 214 and 216 (site E2-6) and 232 (site E2-3) in protective epitopes was demonstrated.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7529989     DOI： 10.1007/bf01309462

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  22 in total

1.  Synthetic peptides of the E2 glycoprotein of Venezuelan equine encephalomyelitis virus. II. Antibody to the amino terminus protects animals by limiting viral replication.

Authors:  A R Hunt; W A Short; A J Johnson; R A Bolin; J T Roehrig
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

2.  [The antigenic structure of glycoprotein E2 in the Venezuelan equine encephalomyelitis virus studied using rat monoclonal antibodies].

Authors:  I A Razumov; E V Agapov; A V Pereboev; E V Protopopova; S D Lebedeva; V B Loktev
Journal:  Vopr Virusol       Date:  1991 Jan-Feb

3.  [Variants of the Venezuelan equine encephalomyelitis virus resistant to the neutralizing action of monoclonal antibodies].

Authors:  E V Agapov; S D Lebedeva; I A Razumov; I V Frolov; A A Kolykhalov; V B Loktev; S V Netesov; L S Sandakhchiev
Journal:  Dokl Akad Nauk SSSR       Date:  1991

4.  Synthetic peptides of Venezuelan equine encephalomyelitis virus E2 glycoprotein. III. Identification of a protective peptide derived from the carboxy-terminal extramembranal one-third of the protein.

Authors:  A J Johnson; A R Hunt; J T Roehrig
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

5.  [The peptide mapping of the E2-2 and E2-6 sites of the E2 glycoprotein in the Venezuelan equine encephalomyelitis virus].

Authors:  V A Sviatchenko; A V Pereboev; E V Agapov; I A Razumov; A N Sabirov; G A Mizenko; V V Samukov; V B Loktev
Journal:  Vopr Virusol       Date:  1993 Jul-Aug

6.  [A monoclonal antibody study of the receptor area of the Venezuelan encephalitis virus].

Authors:  I A Razumov; A V Pereboev; E V Protopopova; A D Khusainova; E V Agapov; E E Mel'nikova; S Ia Gaĭdamovich; V B Loktev
Journal:  Vopr Virusol       Date:  1991 Nov-Dec

7.  Synthetic peptides of Venezuelan equine encephalomyelitis virus E2 glycoprotein. I. Immunogenic analysis and identification of a protective peptide.

Authors:  A R Hunt; A J Johnson; J T Roehrig
Journal:  Virology       Date:  1990-12       Impact factor: 3.616

8.  Properties of monoclonal antibodies directed against the glycoproteins of Sindbis virus.

Authors:  J T Roehrig; D Gorski; M J Schlesinger
Journal:  J Gen Virol       Date:  1982-04       Impact factor: 3.891

9.  Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein.

Authors:  B J Johnson; J R Brubaker; J T Roehrig; D W Trent
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

10.  The T=4 envelope of Sindbis virus is organized by interactions with a complementary T=3 capsid.

Authors:  S D Fuller
Journal:  Cell       Date:  1987-03-27       Impact factor: 41.582
View more
  7 in total

1.  Host alternation of chikungunya virus increases fitness while restricting population diversity and adaptability to novel selective pressures.

Authors:  Lark L Coffey; Marco Vignuzzi
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

2.  Glycoproteins E2 of the Venezuelan and eastern equine encephalomyelitis viruses contain multiple cross-reactive epitopes.

Authors:  A V Pereboev; I A Razumov; V A Svyatchenko; V B Loktev
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.

Authors:  Shirley Lam; Min Nyo; Patchara Phuektes; Chow Wenn Yew; Yee Joo Tan; Justin Jang Hann Chu
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857

4.  Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.

Authors:  Chia Yin Lee; Yiu-Wing Kam; Jan Fric; Benoit Malleret; Esther G L Koh; Celine Prakash; Wen Huang; Wendy W L Lee; Cui Lin; Raymond T P Lin; Laurent Renia; Cheng-I Wang; Lisa F P Ng; Lucile Warter
Journal:  PLoS Pathog       Date:  2011-12-01       Impact factor: 6.823

5.  Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge.

Authors:  Natasha M Kafai; Lauren E Williamson; Elad Binshtein; Soila Sukupolvi-Petty; Christina L Gardner; Jaclyn Liu; Samantha Mackin; Arthur S Kim; Nurgun Kose; Robert H Carnahan; Ana Jung; Lindsay Droit; Douglas S Reed; Scott A Handley; William B Klimstra; James E Crowe; Michael S Diamond
Journal:  J Exp Med       Date:  2022-03-17       Impact factor: 17.579

6.  Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.

Authors:  Pankaj Pal; Kimberly A Dowd; James D Brien; Melissa A Edeling; Sergey Gorlatov; Syd Johnson; Iris Lee; Wataru Akahata; Gary J Nabel; Mareike K S Richter; Jolanda M Smit; Daved H Fremont; Theodore C Pierson; Mark T Heise; Michael S Diamond
Journal:  PLoS Pathog       Date:  2013-04-18       Impact factor: 6.823

7.  Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein.

Authors:  Arthur S Kim; S Kyle Austin; Christina L Gardner; Adam Zuiani; Douglas S Reed; Derek W Trobaugh; Chengqun Sun; Katherine Basore; Lauren E Williamson; James E Crowe; Mark K Slifka; Daved H Fremont; William B Klimstra; Michael S Diamond
Journal:  Nat Microbiol       Date:  2018-11-19       Impact factor: 17.745
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.